TNFRSF17 and Miyoshi myopathy: Likewise, BCMA-specific chimeric antigen receptor (CAR)-T platforms and CAR-NK cells have been developed for adoptive cell therapy in MM [55,59,60,61,62,63,64] (Figure 2).